Does Cymbalta help pelvic pain? (+5 alternatives)
By
Ivan Kahwa
Author bio
Mr Ivan Kahwa is a chemist and phytopharmaceutical scientist with expertise in chemistry, pharmacology, phytochemistry, and Nanobiotechnology. He writes and reviews content on these topics.
Mr Ivan Kahwa’s Highlights:
Guest Researcher at the University of Leipzig, Senior Research Fellow/Scientist, and Lecturer at the Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology.
Professional Experience:
Mr Ivan joined PHARMBIOTRAC as a research fellow/scientist during his master of science tenure. He contributed to the development of most of the phytopharmaceutical products in the project. Furthermore, he participated in carrying out the pharmacological activities of the developed products in laboratory animals such as mice and rats in order to develop proper doses hence leading to pre-clinical studies.
With the above relevant research experience, Ivan started to work with the University of Leipzig on collaborative projects with Mbarara University to develop the chemistry of Ugandan Medicinal plants and their pharmacological activities. This was coupled with several consultative positions by different German NGOs. Mr. Kahwa is also a supporting in the teaching and learning at the Departments of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, Mbarara University of Science and Technology.
With the increase in antimicrobial resistance globally, Ivan retooled his thinking towards developing new naturally derived antibiotic regimens from Ugandan propolis with the assistance of nanotechnology to improve their delivery to microbial cells. Kahwa has also published over 28 articles in peer-reviewed journals and he is currently reviewing for many journals.
Education:
2023-2027: PhD in Pharmaceutical Sciences (ongoing) with a focus on Pharmaceutical Microbiology and Nanobiology at Mbarara University of Science and Technology.
2022: 2Msc. in Pharmacognosy and Natural Medicine Science at Mbarara University of Science and Technology.
2018: Bachelor of Science (Chemistry) at Mbarara University of Science and Technology.
Publications:
▪ Iqbal, S., Jabeen, F., Kahwa, I., & Omara, T. 2023. Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-023-09804-7
▪ Gupta, A. K., Yadav, R., Sharma, S., Sawale, J., & Kahwa, I. 2023. Anti-ageing Activity and Antioxidant Activity of Methanol Extracts of Leaves and Flowers of Salvia officinalis and Rosmarinus officinalis. Journal of Young Pharmacists, 15(3), 448–455. https://doi.org/10.5530/jyp.2023.15.60
▪ Tolo, C.U., Kahwa, I., Nuwagira, U., Weisheit, A. and Ikiriza, H., 2023. Medicinal plants used in treatment of various diseases in the Rwenzori Region, Western Uganda. Ethnobotany Research and Applications, 25, pp.1-16.
https://ethnobotanyjournal.org/index.php/era/article/view/4683
▪ Kahwa, I., Ajayi, C.O., Yadav, R., Chauhan, N.S., Shah, K., Abdelgadir, A.A., Shegena, E.A., Daniel, S., Omara, T., Asiimwe, J.B. and Ikiriza, H., 2023. Pharmacognostic and phytochemical studies as an invaluable approach for correct identification of medicinal plants: The case of Artemisia vulgaris L. substituted for Artemisia annua L. in Western Uganda. TMR Integr Med, 7, p.e23004.
https://doi.org/10.53388/TMRIM202307004
▪ Nalimu, F., Oloro, J., Kahwa, I. and Ogwang, P.E., 2021. Review on the phytochemistry and toxicological profiles of Aloe vera and Aloe ferox. Future Journal of Pharmaceutical Sciences, 7, pp.1-21.
https://doi.org/10.1186/s43094-021-00296-2
▪ Elamin, O.H.S., Ali, M.A., Elgezuli, I.A.A., Bashir, M.A. and Kahwa, I., 2021. Diagnosis of pre-and post-treatment of echinococcus granulosus with counter current immune electrophoresis and bacterial co-agglutination. Journal of Microbiology and Infectious Diseases, 11(02), pp.88-94.
https://doi.org/10.5799/jmid.951600
Published book Chapter
▪ Kahwa, I., Ayesiga, I., Nakalema, S., Alinaiswe, R., Mbabazi, R. and Iqbal, S., 2023. Natural products in the management of onchocerciasis. In Natural Products in Vector-Borne Disease Management (pp. 63-80). Academic Press. Book Chapter.
https://doi.org/10.1016/B978-0-323-91942-5.00012-4
Submitted manuscripts Under Review:
▪ Comparison of the Wound Healing Activity of the Leaf and Leaf Ash Extracts of Vernonia amygdalina in Rats. Journal name: Clinical Phytoscience
▪ Ethnobotanical Survey of Medicinal plants used in the management of cancer in Uganda. Journal name: Journal of Herbal Medicine
▪ Ethnobotanical survey and phytochemical screening of medicinal plants used in treatment of epilepsy by PROMETRA-Uganda Traditional Health Practitioners in Mpigi District, Uganda. Journal name: Journal of Ethnopharmacology
Submitted book chapters under review
1.Book title: Algae as a Natural Solution for Water-Food-Energy Nexus, Section 4: Microalgae and cyanobacteria for food applications, Chapter 4.6: Safety, toxicological and allergenic aspects of using algae for food. Authors: Christine Kyarimpa, Tom Omute, Caroline K. Nakiguli, Alice V. Khanakwa4, Christopher Angiro, Ivan Kahwa, Fortunate Ahumuza, Timothy Omara*. Publisher: Springer Nature Singapore Pte Ltd. 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore.
2.Book title: Nutraceuticals Inspiring the Contemporary Therapy for Lifestyle Diseases. Chapter: Nutraceutical applications of Seaweeds and their Phytocompounds in Nutrition and Treatment of Diseases. Authors: Ivan Kahwa, Timothy Omara , Innocent Ayesiga , Gael Noel Neh Neba Ambe , Zehbanaz Javidbhai Panwala , Rachel Mbabazi , Shabnoor Iqbal , Christine Kyarimpa , Christine Betty Nagawa , Kamal Shah ,Nagendra Singh Chauhan* Publisher: CRC Press
You can view my works on the following professional sites:
Research Gate: https://www.researchgate.net/profile/Ivan-Kahwa
Google Scholar: https://scholar.google.com/citations?user=tOwrvqoAAAAJ&hl=en
ORCID: https://orcid.org/0000-0002-6440-3437
Linkedin: https://de.linkedin.com/in/ivan-kahwa-865450159
In this article, we will discuss the role of Cymbalta in the management of pelvic pain. We will also discuss the research studies suggesting the effectiveness of Cymbalta in pelvic pain, as well as the alternative mediations for managing pelvic pain if Cymbalta fails to treat it.
Does Cymbalta help pelvic pain?
Yes, Cymbalta does help pelvic pain. While the exact mechanism of Cymbalta in pain management remains unclear, recent studies have explored its potential as an effective medication for pelvic pain (4).
Cymbalta is an antidepressant medication frequently employed in the treatment of depression, fibromyalgia, and anxiety. Research studies have also reported its potential to be used in the management of back pain, joint pain, and pelvic pain (1).
While it is generally considered a safe medication that is well-tolerated by individuals, it may cause certain side effects in some, such as dizziness, tiredness, drowsiness, headache, vomiting, and appetite and weight changes (1).
What is the dosage of Cymbalta for pelvic pain?
The recommended dosage for Cymbalta in the treatment of pelvic pain is typically 60mg daily. However, it’s important to note that the duration of treatment can vary from person to person. Studies indicate that individuals may experience relief from pelvic pain with Cymbalta after a few weeks to months of consistent use (2).
While the response to treatment varies, research suggests that a duration of approximately 4 months may be beneficial for managing pelvic pain effectively (2). Individuals must follow their healthcare provider’s guidance regarding the dosage and duration of Cymbalta therapy, as adjustments may be made based on the individual’s response and overall health.
What does research suggest?
In a research study, Cymbalta was employed as part of the management strategy for pelvic pain, administered at a dosage of 60 mg daily, in combination with doxazosin. The study aimed to assess the effectiveness of this combination in alleviating pelvic pain symptoms.
Results showed a gradual improvement, with 30% experiencing relief after 4 weeks. The effectiveness increased over time, and after 24 weeks, about 89% of patients showed significant improvement in pelvic pain (3).
In an additional research study, the use of Cymbalta showcased its effectiveness in addressing pelvic pain among elderly patients. This positive outcome was achieved when Cymbalta was employed in combination with olanzapine, suggesting a synergistic approach to pain management in patients with chronic pelvic pain syndrome (4).
What to do if Cymbalta fails to manage pelvic pain?
Treatment with Cymbalta usually takes a few weeks to show improvement in your symptoms. However, if you find that Cymbalta is not relieving your pelvic pain even after weeks of treatment, you should consult your healthcare provider. They will assess your condition and determine the cause of treatment failure.
In some cases, increasing the dosage of Cymbalta is helpful in achieving therapeutic outcomes. However, you should be cautious while using a higher dosage of Cymbalta, as it may increase the likelihood of side effects associated with the medication.
Alternatively, your healthcare provider may recommend an alternative to Cymbalta for managing your pelvic pain. It is important to note that discontinuation of Cymbalta should be done under the guidance of your healthcare provider to avoid unwanted side effects associated with the sudden discontinuation of this medication.
What are the alternatives to Cymbalta for pelvic pain?
If Cymbalta proves ineffective in managing pelvic pain symptoms, your healthcare provider may prescribe alternative medications based on the underlying cause and severity of the pain. These alternatives may include (5,6,7):
- fluoxetine
- citalopram
- venlafaxine
- mirtazapine
- anticonvulsants (gabapentin, pregabalin)
However, it is crucial to consult with a healthcare professional for a proper diagnosis and a personalized treatment plan. These medications may have potential side effects, and the selection of an appropriate medication should be based on an assessment of their risks and benefits.
In my opinion, Cymbalta is a good option for managing pelvic pain, considering its safety and efficacy profile. It is less likely to cause unwanted and serious side effects in individuals. However, you should not take any medication without consulting your healthcare provider.
Always discuss your symptoms with your healthcare provider to ensure the most suitable and effective treatment for your specific condition.
Was this helpful?
References
1.-
Dhaliwal JS, Spurling BC, Molla M. Duloxetine. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549806/
2.-
Giannantoni A, Porena M, Gubbiotti M, Maddonni S, Di Stasi SM. The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2014 Feb;83(2):400-5. doi: 10.1016/j.urology.2013.09.024. Epub 2013 Nov 12. PMID: 24231216. https://pubmed.ncbi.nlm.nih.gov/24231216/
3.-
Zhang M, Li H, Ji Z, Dong D, Yan S. Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study. Medicine (Baltimore). 2017 Mar;96(10):e6243. doi: 10.1097/MD.0000000000006243. PMID: 28272220; PMCID: PMC5348168. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348168/
4.-
Bi, Bo & Shan, Liping & Zhou, Die. (2018). Combined Use of Duloxetine and Olanzapine in the Treatment of Urologic Chronic Pelvic Pain Syndromes Refractory to Conventional Treatment: A Case Report. Clinical Psychopharmacology and Neuroscience. 16. 122-125. 10.9758/cpn.2018.16.1.122.
5.-
Karp JF. Venlafaxine XR and chronic pelvic pain syndrome. J Clin Psychiatry. 2004 Jun;65(6):880-1. doi: 10.4088/jcp.v65n0622e. PMID: 15291672. https://pubmed.ncbi.nlm.nih.gov/15291672/
6.-
Xia D, Wang P, Chen J, Wang S, Jiang H. Fluoxetine ameliorates symptoms of refractory chronic prostatitis/chronic pelvic pain syndrome. Chin Med J (Engl). 2011 Jul;124(14):2158-61. PMID: 21933619. https://pubmed.ncbi.nlm.nih.gov/21933619/
7.-
Brown CS, Franks AS, Wan J, Ling FW. Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. J Reprod Med. 2008 Mar;53(3):191-5. PMID: 18441724. https://pubmed.ncbi.nlm.nih.gov/18441724/
Find a supportive therapist who can help with Depression.
Discover the convenience of BetterHelp, an online therapy platform connecting you with licensed and accredited therapists specialized in addressing issues such as depression, anxiety, relationships, and more. Complete the assessment and find your ideal therapist within just 48 hours.
AskYourPharm is user-supported. We may earn a commission if you sign up for BetterHelp’s services after clicking through from this site
